Nature Biotechnology published advancements in targeted cancer therapies, including antibody–bottlebrush prodrugs that offer expanded payload flexibility and improved delivery over traditional antibody-drug conjugates. Concurrently, researchers from Stanford and the Arc Institute developed STF-1623, a potent ENPP1 inhibitor that enhances innate immune checkpoint blockade by prolonging tumor-specific drug residence time, representing a new strategy to treat immunologically 'cold' tumors resistant to existing immunotherapies.